Detalhe da pesquisa
1.
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
Lancet Oncol
; 19(1): 76-86, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29248236
2.
Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
Prostate
; 76(13): 1218-26, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27338150
3.
Practical Guidance on [177Lu]Lu-PSMA-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling.
Clin J Oncol Nurs
; 27(5): 539-547, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37729454
4.
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.
Sci Transl Med
; 7(269): 269ra2, 2015 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25568070
5.
A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.
Cancer Chemother Pharmacol
; 67(2): 431-8, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20445979
6.
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.
J Natl Cancer Inst
; 98(23): 1714-23, 2006 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-17148773